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Importance of chronic pain in the rheumatic 
diseases
Although pain is commonly the patients’ utmost priority 
and the reason most patients seek rheumatologic consul-
tation, the medical community has historically had a 
poor understanding of the etiology, mechanisms and 
treatment of pain. Rheumatologists often consider pain a 
peripheral entity, but there is great discordance between 
pain severity and purported peripheral causes of pain, 
such as inﬂ  ammation and structural joint damage (for 
example, cartilage degradation, erosions).
In recognition of the importance of pain in the 
rheumatic diseases, the American College of Rheuma-
tology Pain Management Task Force established an 
initia  tive to increase awareness and call for organized 
research and education [1]. Th   is initiative emphasizes the 
need for high-quality, quantitative research to understand 
the mechanisms underlying individual diﬀ  erences in pain 
among patients with rheumatic disease. Currently, most 
advances in the study of pain mechanisms have been in 
non-inﬂ   ammatory diseases, such as ﬁ  bromyalgia  [2]. 
Th  ese studies have highlighted the role of central pain-
processing mechanisms, such as loss of descending 
analgesic activity and central pain augmentation or sensi-
tization. Some pain researchers also believe that these 
mechanisms may have a signiﬁ   cant impact on pain 
severity among patients with osteoarthritis (OA) and 
rheuma  toid arthritis (RA), diseases that have historically 
been associated with peripheral pain due to joint damage 
and inﬂ  ammation.
In the present review we give a brief overview of the 
basic biology of acute and chronic pain, including the 
role of central pain-processing defects. We discuss the 
role of these mechanisms in diseases commonly seen in 
rheumatology practices (for example, ﬁ  bromyalgia, OA 
and RA) and consider potential treatments that may 
correct deﬁ  cits in central pain processing.
Basic biology of pain in healthy individuals
To determine the cause of pain, rheumatologists fre-
quently categorize pain into acute pain and chronic pain. 
Acute pain typically lasts from seconds to weeks or 
months. Acute pain is often sudden in onset, as it is 
usually the direct result of a noxious stimulus. In 
contrast, chronic pain is, by deﬁ  nition, present for at least 
3 months. Chronic pain may persist because the original 
inciting stimulus is still present and/or because changes 
to the nervous system have occurred, making it more 
sensitive to pain.
Acute pain
Acute pain develops when a stimulus, such as pressure, 
heat or inﬂ   ammation, is presented to the body. 
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the signals to the central nervous system (CNS) via nerve 
ﬁ  bers that extend into the dorsal horn of the spinal cord. 
Th  e specialized receptors include low-threshold recep-
tors that respond to non-noxious levels of stimuli, and 
high-threshold receptors that sense noxious stimuli 
(nociceptors). Both nerve ﬁ   bers reside in soft tissue 
throughout the body, including the muscle, skin and 
internal organs.
Two types of nociceptors, the Aδ aﬀ  erent and the C 
aﬀ  erent, are responsible for the sensation and diﬀ  eren-
tiation of mechanical, chemical and heat stimuli. Th  e  Aδ 
nerve ﬁ  ber has two classes, Type I and Type II, which 
respond to mechanical and heat stimuli. Type I ﬁ  bers 
have higher heat thresholds than Type II ﬁ  bers, while 
Type II ﬁ bers have higher mechanical thresholds than 
Type I ﬁ  bers [3]. Consequently, the Type I Aδ aﬀ  erents 
usually transmit noxious mechanical stimuli while the 
Type II Aδ aﬀ  erents often transmit noxious heat stimuli. 
Th   e C nerve ﬁ  bers detect mechanical and heat stimuli, as 
well as chemical stimuli. Compared with pain mediated 
by Aδ ﬁ  bers, pain mediated by unmyelinated C ﬁ  bers 
tends to be poorly localized [4].
Chronic pain
Chronic pain is associated with many rheumatologic 
conditions, varying from non-inﬂ  ammatory syndromes, 
such as ﬁ  bromyalgia, to systemic inﬂ  ammatory diseases, 
such as RA. Depending on the condition, as well as 
individual factors, diﬀ   ering pain mechanisms are in-
volved. Mechanisms of chronic pain can be divided into 
peripheral mechanisms and central mechanisms.
Peripheral pain mechanisms stem from abnormalities 
in the peripheral nerves, leading to local areas of 
enhanced pain sensitivity. Th  e most commonly cited 
peripheral pain mechanism besides direct nociceptive 
input is peripheral sensitization, which probably plays 
important roles in chronic pain mediated by OA and RA. 
Th   is topic is covered in depth by Schaible and colleagues 
in an earlier manuscript in this Biology of Pain review 
series [5].
Central pain mechanisms operate at the level of the 
CNS, leading to enhanced widespread pain sensitivity. 
Individuals with augmented central pain processing will 
display diﬀ  use hyperalgesia (increased pain in response 
to normally painful stimuli) and allodynia (pain in 
response to normally nonpainful stimuli).
Abnormalities in central pain processing are divided 
into abnormalities in the descending facilitatory and 
inhibitory pain pathways, and central sensitization 
(Figure 1). Th   e descending pain pathways descend from 
the brainstem, hypothalamus and cortical structures, and 
modulate sensory input from primary aﬀ  erent ﬁ  bers and 
projection neurons in the dorsal horn of the spinal cord 
[6]. Th  e best characterized descending analgesic path-
ways are the serotonergic–noradrenergic pathway and 
the opioidergic pathway. Th  ese pathways lead to the 
release of serotonin, norepinephrine and endogenous 
opioids, which inhibit the release of excitatory neuro-
transmitters such as glutamate. Th  ese pathways are 
activated in response to noxious stimuli, leading to a 
widespread decrease in pain sensitivity after exposure to 
an acutely painful stimulus. In chronic pain syndromes, 
descending analgesic activity is often impaired or 
absent – hence the term loss of descending analgesia.
In the present review, loss of descending analgesia is 
used synonymously with the term loss of diﬀ  use noxious 
inhibitory controls. Experimentally, diﬀ  use noxious inhi-
bi  tory control is commonly assessed by exposing subjects 
to two types of stimuli: the conditioning stimulus, and 
the test stimulus. Th   e conditioning stimulus is an acute 
noxious stimulus that activates descending analgesic 
pathways, leading to a diﬀ  use decrease in pain sensitivity 
throughout the body [7]. In healthy controls, a wide 
range of noxious stimuli – including ice-cold water, 
contact heat and tourniquet ischemia – are all eﬀ  ective 
conditioning stimuli, produc  ing increased pain thres  h-
olds throughout the body [7]. Th   e test stimulus is a pain-
ful stimulus that is applied at baseline and during/after 
exposure to the conditioning stimulus. Th   e magnitude of 
the descending analgesic response is the diﬀ  erence 
between the pain rating of the test stimulus before 
exposure to the conditioning stimu  lus and the pain rating 
of the test stimulus after exposure to the conditioning 
stimulus [7].
When evaluating these studies, it is important to 
under  stand that, although commonly used to assess 
descen  ding analgesia, these studies do not speciﬁ  cally 
localize the areas of pain modulation to the descending 
spinal tracts. Changes in pain threshold after noxious 
pain stimulation may also partly reﬂ   ect changes in 
attention (for example, distraction) or other processes 
that inﬂ   uence pain perception. To directly assess the 
descen  ding spinal pathways, electrophysiologic assess-
ments of the spinal nociceptive ﬂ  exion reﬂ  ex must be 
performed.
While descending analgesic pathways are typically 
toni  cally active and inhibit the upward transmission of 
pain signals, other descending pain-processing mecha-
nisms involve enhanced activity down the descending 
facilitatory pain pathways that lead to generalized 
increases in sensory sensitivity [8]. Th  e role of these 
facilitatory pathways, however, has not been well estab-
lished in human studies.
In addition to descending inhibitory and facilitatory 
pathways, central sensitization also leads to enhanced 
CNS neuron excitability and increased transmission of 
pain signals. In the literature, the term central 
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general abnormalities in central pain processing (which, 
in the present review, we will refer to as central 
augmentation); and to describe a speciﬁ  c defect in central 
pain process  ing associated with activation of N-methyl-
d-aspartate (NMDA) receptor channels (which we will 
refer to as central sensitization).
Central sensitization occurs largely as a result of en-
hanced release of glutamate and substance P at the level 
of the spinal cord. Glutamate is the major excitatory 
neurotransmitter in the nervous system, and it acts on 
three receptor subsets: the α-amino-3-hydroxy-5-methyl-
4-isoxazeloproprionic acid receptor, the NMDA receptor 
and the G-protein-coupled metabotropic family of 
receptors. While the α-amino-3-hydroxy-5-methyl-4-
isoxazelo  proprionic acid receptor is responsible for the 
baseline response to noxious stimuli, the NMDA receptor 
enhances and extends the pain response [9]. NMDA 
receptor activation results in calcium inﬂ  ux, stimulating 
calcium/calmodulin-dependent kinases and extracellular 
signal-regulated kinases. Th  ese changes modulate CNS 
plasticity, resulting in the hyperalgesia and allodynia that 
characterize central sensitization [9].
Experimentally, central sensitization is characterized 
by diﬀ  use pain sensitivity and increased pain severity 
during and after repeated stimuli. Individuals with 
central sensitization have low thermal and mechanical 
thresholds in a diﬀ  use pattern, reﬂ  ecting enlargement of 
the spinal cord neuron receptive ﬁ   elds [4]. Repeated 
stimulation results in painful after-sensations that persist 
after a stimulus is withdrawn; and results in enhanced 
temporal summation of pain such that the pain rating for 
the last stimulus is higher than the pain rating for the ﬁ  rst 
stimulus, even though the stimuli are exactly the same. 
NMDA receptor antagonists, such as dextromethorphan 
and ketamine, inhibit temporal summation [10-12].
Studies sugge    st that maintenance of central augmen-
tation requires persistent noxious peripheral input, even 
in syndromes such as ﬁ  bromyalgia, which is characterized 
by the absence of well-deﬁ  ned, localized, pain-causing 
lesions [13,14]. A recent study of 68 ﬁ  bromyalgia patients 
with myofascial pain syndromes and 56 ﬁ  bromyalgia 
Figure 1. Descending pain pathways and central sensitization. Descending pain pathways and central sensitization modulate the pain 
response in the dorsal horn of the spinal cord. Descending analgesic pathways include the serotonin–norepinephrine and opioidergic descending 
pathways, which dampen pain sensitivity response. Loss of descending analgesia leads to hyperalgesia and allodynia. Central sensitization occurs 
through the action of glutamate on the N-methyl-D-aspartate (NMDA) receptor, resulting in an increase in intracellular calcium levels and kinase 
activation, leading to hyperalgesia and allodynia.
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trigger point injections and hydroelectrophoresis 
ameliorate ﬁ  bromyalgia pain and increase pain thresholds 
at sites distant from the therapeutic interventions [15], 
providing further evidence that painful peripheral stimuli 
contribute to the perpetuation of central augmentation.
Fibromyalgia
Fibromyalgia is the prototypical non-inﬂ  ammatory chronic 
pain syndrome. Th  e disease is characterized by chronic 
widespread pain and associated symptoms, including 
sleep problems, fatigue, cognitive dysfunction and 
depression. Quantitative sensory testing methods have 
consistently identiﬁ  ed abnormalities in pain percep  tion 
among ﬁ   bromyalgia patients (Table 1). Most notably, 
patients with ﬁ  bromyalgia have diﬀ  usely lower pressure 
pain thresholds than healthy controls [16]. Th  is diﬀ  use 
hyperalgesic state of central augmentation of pain 
processing has been repeatedly identiﬁ   ed using func-
tional neuroimaging techniques [17,18] and may partly 
be due to speciﬁ   c defects such as loss of descending 
analgesic activity and central sensitization.
Evidence for the role of defects in descending analgesic 
activity in ﬁ   bromyalgia comes from studies of condi-
tioned pain modulation [19-21]. In a study of 26 healthy 
controls and 25 ﬁ  bromyalgia patients, heat stimulation of 
the foot increased pain thresholds to electric stimulation 
of the forearm among healthy controls but not among 
ﬁ  bromyalgia patients [19]. Similarly, tourniquet ischemic 
pain increased pressure pain threshold in 10 healthy 
controls but not in 10 ﬁ  bromyalgia patients [20], and a 
noxious cold stimulus reduced heat pain ratings among 
20 healthy controls but not among 45 ﬁ  bromyalgia 
patients [21].
Th   ese defects in inhibitory pain responses may be due 
to blunted activity of the descending serotonergic–nor-
adrenergic system. Fibromyalgia patients have reduced 
serum levels of serotonin and its precursor, l-tryptophan, 
as well as reduced levels of the principal serotonin 
metabolite, 5-hydroxyindoleacetic acid, in their cerebral 
spinal ﬂ   uid [22]. Levels of 3-methoxy-4-hydroxyphen-
ethylene, the principal metabolite of norepinephrine, are 
also lower in the cerebral spinal ﬂ   uid of ﬁ  bromyalgia 
patients compared with healthy controls [22]. In contrast, 
biochemical and imaging ﬁ   ndings suggest that ﬁ  bro-
myalgia patients actually have increased activity of 
endogenous opioidergic systems, which is consistent with 
anecdotal experience that opioids are ineﬀ  ective anal-
gesics in patients with ﬁ   bromyalgia and related 
conditions [23,24].
Th  e evidence for central sensitization in ﬁ  bromyalgia 
predominantly consists of studies comparing the magni-
tude of temporal summation in ﬁ  bromyalgia  patients 
with healthy controls. Although both ﬁ  bromyalgia 
patients and healthy controls experience temporal sum-
ma  tion, the magnitude of temporal summation may be 
slightly greater in ﬁ  bromyalgia patients [25]. Th  e  magni-
tude of temporal summation is decreased by treatment 
with either fentanyl injections or ketamine, an NMDA 
antagonist [10,12].
In addition to heightened sensitivity to pain, ﬁ  bro-
myalgia patients are also more sensitive to a variety of 
other sensory stimuli [26,27]. Th   is polysensory augmen-
tation may partly be due to enhanced neural activity that 
has been consistently observed in brain regions such as 
the insula, a region known to code for the intensity of all 
sensory information [17]. Previous studies suggest that 
the anterior insula is involved in the aﬀ  ective/emotional 
modulation of pain processing, while the posterior insula 
is involved in the sensory/discriminative processing of 
pain [28]. Compared with controls, ﬁ  bromyalgia patients 
have higher levels of glutamate in the posterior insula, 
and changes in glutamate levels in the posterior insula 
are correlated with changes in pain and tenderness after 
acupuncture [29,30]. Th   ese studies suggest that at least a 
component of pain in ﬁ  bromyalgia is a result of sensory 
ampliﬁ  cation, rather than just aﬀ  ective processing.
Genetic studies also support an association between 
the serotonergic–noradrenergic system and ﬁ  bromyalgia. 
In candidate gene studies, polymorphisms in the meta  bo-
lism and transport of monoamines (for example, cate-
chol amine-o-methyltransferase, serotonin 5-hydroxy  tryp-
ta  mine type 2a receptor, serotonin transporter) have been 
associated with the diagnosis or severity of ﬁ  bromyalgia 
[31-35]. Most of these studies were small, however, and 
conﬂ  icting data exist – with some studies reporting no 
Table 1. Peripheral and central quantitative sensory testing fi  ndings in fi  bromyalgia, osteoarthritis and rheumatoid 
arthritis
 Peripheral  fi  ndings  Central fi  ndings
  Low pain  Low pain  Loss of descending   
  thresholds at  thresholds in a  analgesia (conditioned  Temporal  Expanded areas
 aff  ected sites  widespread distribution  pain modulation)  summation  of hyperalgesia
Fibromyalgia  X X X X X
Osteoarthritis  X X X X X
Rheumatoid  arthritis  X  X  X  X
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38]. Future studies, incorporating a larger number of 
ﬁ   bromyalgia patients and/or utilizing meta-analysis 
techniques, are needed.
In addition to genetic studies, a recent surge of interest 
has surrounded the use of functional magnetic resonance 
imaging (fMRI) to study pain in a more quantitative, 
objec  tive manner. Th   is area of research, however, is still 
relatively new. As such, we present the following results 
as preliminary evidence for the role of the CNS in pain 
modulation, rather than as well-established facts.
In one of the early studies of fMRI in ﬁ  bromyalgia, 
Gracely and colleagues reported that ﬁ  bromyalgia patients, 
compared with controls, exhibit enhanced activation in 
the contralateral primary somatosensory cortex (SI), 
inferior parietal lobe, insula, anterior cingulate cortex, 
posterior cingulate cortex, ipsilateral secondary somato-
sensory cortex (SII) cortex, bilateral superior temporal 
gyrus and cerebellum when exposed to experimental pain 
of the same magni  tude (for example, same pressure) [17]. 
When exposed to experimental pain stimuli rated of 
similar intensity (moderate), however, ﬁ  bromyalgia 
patients exhibited activation in the same neural struc  tures 
(contralateral SI, SII, contralateral superior temporal 
gyrus, inferior parietal lobe, contralateral putamen, ipsi-
lateral cerebel  lum and contralateral insula) as controls. 
Th   ese observations provided the ﬁ  rst  fMRI-based 
evidence for central augmentation of pain sensitivity in 
ﬁ  bromyalgia.
Cook and colleagues noted similar ﬁ  ndings in a study 
examining responses to heat stimuli [39]. In addition, 
their study reported post hoc analyses showing no neural 
activation in the periaqueductal gray region of ﬁ  bro-
myalgia patients exposed to painful heat stimuli but 
signiﬁ  cant activity in the periaqueductal gray region of 
healthy controls exposed to painful heat stimuli. Because 
previous studies have suggested that the periaqueductal 
gray region is involved in descending pain modulation, 
these ﬁ  ndings were interpreted as possible evidence for 
loss of descending analgesia among ﬁ  bromyalgia patients. 
A more recent article by Jensen and colleagues showed 
similar decreases in neuronal activation in the anterior 
cingulate cortex, a region also involved in pain 
modulation [40].
Th  e fMRI techniques examining resting-state func-
tional connectivity have also identiﬁ  ed the default mode 
network as a potential modulator of spontaneous clinical 
pain in ﬁ  bromyalgia patients. Th   e default mode network 
consists of neural regions (medial frontal gyri, hippo-
campus, lateral temporal cortex, posterior cingulate 
cortex, precuneus, inferior parietal lobe) that are active at 
rest and may be involved in self-referential thought. In a 
study of 18 ﬁ  bromyalgia patients and 18 age-matched 
and sex-matched controls, Napadow and colleagues 
noted that connectivity between the default mode 
network and the insula was positively correlated with 
clinical pain severity [41].
Osteoarthritis
OA is a common degenerative joint disease, characterized 
by damage to cartilage and bone, which aﬀ  ects approxi-
mately 27 million people in the United States [42]. 
Individuals with OA often suﬀ   er from chronic pain, 
ultimately leading to signiﬁ  cant disability and healthcare 
costs. Despite the signiﬁ   cant impact of pain in OA 
patients, little is known about the causes of the pain 
associated with OA.
On a population level, pain intensity (via patient self-
report) correlates poorly with peripheral joint damage 
assessed by the Kellgren–Lawrence radiologic classiﬁ  -
cation criteria [43]. Within individuals, however, pain 
severity is strongly associated with radiographic damage 
[44]. Taken together, these studies suggest that other 
mechanisms of pain that are not knee speciﬁ  c  (for 
example, enhanced pain sensitivity due to alterations in 
central pain processing) may play a role in the variability 
in pain severity across individuals.
Studies utilizing quantitative sensory testing indicate 
that OA patients are more sensitive to experimental pain 
stimuli than healthy controls (Table 1). Most studies have 
focused on pain sensitivity at sites close to aﬀ  ected joints, 
showing that OA patients have lower mechanical and 
thermal pain thresholds (for example, higher pain sensi  ti-
vi  ty) than healthy controls [45-49]. Intriguingly, O’Driscoll 
and Jayson also reported low-pressure pain thresholds at 
the forehead, a clinically nonpainful site, unaﬀ  ected by 
OA [50]. Similarly, among 15 patients with OA of the hip, 
Kosek and Ordeberg noted increased sensitivity to 
pressure, ischemia and innocuous warm stimuli at the 
aﬀ   ected hip and at the contralateral hip, indicating a 
diﬀ  use process extending beyond just the aﬀ  ected joint. 
Th  ese studies suggest that OA pain, histori  cally con-
sidered a peripheral entity, may also be modulated via 
wide  spread mecha  nisms controlled by the CNS.
Assessments of the wide  spread nature of pain 
sensitivity in OA have provided further support for the 
role of central pain mechanisms in OA. Bajaj and 
colleagues infused hypertonic saline into the tibialis 
anterior muscles of 14 OA patients and of 14 age-
matched and sex-matched controls. OA patients reported 
increased pain intensity and larger pain areas, extending 
to the toes, whereas healthy controls reported lower pain 
intensity with the distribution of pain ending near the 
ankle. Th   e authors attributed these ﬁ  ndings to changes in 
central pain mechanisms [51]. In a larger study of 62 
female knee OA patients and 22 age-matched healthy 
controls, Imamura and colleagues highlighted the 
widespread distribution of pain sensitivity, showing 
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dermatome levels, myotomal hyperalgesia at nine lower 
extremity muscle groups, and sclerotomal hyperalgesia at 
eight sites across the lower back and legs. Th  e authors 
speculated that both peripheral and central mechanisms 
contribute to the chronic pain state, with peripheral 
mechanisms being more important in the early stages, 
and central mechanisms dominating in the later stages 
[52].
Additional evidence for defects in central pain pro-
cessing comes from studies assessing speciﬁ  c  pain-
processing mechanisms, such as loss of descending 
analgesic activity. In a study of 48 knee OA patients and 
24 age-matched and sex-matched controls, OA patients 
exhibited greater loss of descending analgesic activity 
than healthy controls [49] – a ﬁ   nding similar to the 
previous study by Kosek and Ordeberg of 15 hip OA 
patients [47]. Th  e study by Kosek and Ordeberg was 
particularly interesting because it showed that loss of 
descending analgesic activity is contingent upon the 
chronic pain state and that loss of descending analgesic 
activity can be reversed [47]. After the initial evaluation, 
13 out of 15 hip OA patients underwent surgery, resulting 
in signiﬁ  cant clinical pain relief. When the patients were 
reassessed 6 to 14 months after surgery (when pain-free), 
they exhibited signiﬁ   cant increases in pain thresholds 
com  pared with pre surgery. Postsurgery pain thresholds 
were similar to pain thresholds among healthy controls. 
Furthermore, modulation of pain through descending 
analgesic pathways was restored. Th  ese results suggest 
that dysfunctional central pain mechanisms are asso-
ciated with the chronic pain state, and removal of the 
inciting pain stimulus may lead to normalization of 
central pain processing [47].
In addition to loss of descending analgesic activity, 
central sensitization may also alter pain processing 
among OA patients. In a study examining the eﬀ  ects of 
repeated pressure stimulation on pain sensitivity, temporal 
summation at the knee and tibialis anterior muscle was 
signiﬁ   cantly greater among patients with knee OA 
compared with controls [49].
Studies utilizing fMRI during quantitative sensory 
testing have also shown enhanced activity in the peri-
aqueductal gray matter of OA patients compared with 
healthy controls [48]. Th  is  ﬁ  nding was interpreted as an 
increase in activity of the descending facilitatory path-
ways, a mechanism that would have the same net eﬀ  ect 
as a decrease in descending analgesic activity. Notably, 
this ﬁ  nding is the opposite of that found by Cook and 
colleagues in ﬁ   bromyalgia patients [39]. Cook and 
colleagues reported lower levels of activity in the 
periaqueductal gray matter of ﬁ  bromyalgia  patients 
compared with pain-free controls, which the authors 
interpreted as an impairment in descending analgesic 
pathways. Other studies using fMRI have suggested     that 
OA-related knee pain is modulated by the medial pain 
system, a network of brain structures associated with the 
aﬀ  ective dimension of pain processing [53].
Rheumatoid arthritis
In contrast to ﬁ  bromyalgia and OA, RA is characterized 
by systemic inﬂ   ammation. Although inﬂ  ammation 
contri  butes to pain in RA, it may not be the only factor. 
For some patients, pain does not improve despite 
treatment with anti-inﬂ  ammatory  disease-modifying 
anti-rheumatic drugs.  In a cross-sectional analysis  of 
12,090 RA patients recruited from rheumatology prac-
tices, pain levels were almost constant over RA duration, 
even though most participants were treated with a 
disease-modifying anti-rheumatic drug, an anti-TNF 
agent or both [54]. A large longitudinal study, consisting 
of 882 RA patients, reported that pain initially decreased 
during the ﬁ  rst 3 years after diagnosis but subsequently 
increased over time. Th  e authors speculated that the 
initial decrease in pain was due to control of inﬂ  am-
mation while the later rise in pain was attributed to other 
pain pathways [55].
Although few studies have speciﬁ  cally examined the 
role of central pain-processing mechanisms in RA, 
studies utilizing dolorimetry to assess pain thresholds 
suggest that these other pathways may include deﬁ  cits in 
central pain processing. Deﬁ  cits in central pain process-
ing are characterized by enhanced pain sensitivity in a 
widespread distribution, and studies have consistently 
shown that RA patients have lower pressure pain 
thresholds (higher pain sensitivity) than healthy controls 
at joint and nonjoint sites [56-58].
Only one study has directly examined the role of 
descending analgesic activity in RA patients [59]. Th  e 
study compared the magnitude of descending analgesic 
activity in 11 patients with RA of short duration to 11 
healthy controls and in 10 patients with RA of long 
duration to 10 healthy controls. Th  e magnitude of 
descending analgesic activity in both groups of RA 
patients was less than the magnitude of descending 
analgesic activity in healthy controls. Th  ese diﬀ  erences 
were not statistically signiﬁ  cant [59], but given the small 
samples sizes it was diﬃ   cult to determine whether there 
really was no diﬀ   erence between the two groups or 
whether the study was underpowered to detect an eﬀ  ect.
A few small studies have provided support for the role 
of central sensitization in pain augmentation among RA 
patients. Wendler and colleagues demonstrated using 
electroencephalography that, compared with age-matched 
and sex-matched controls, RA patients had enhanced 
cortical responses to repeated noxious stimu  lation, suggest-
ing changes in CNS modulation of pain [60]. Morris and 
colleagues showed that capsaicin induces a larger area of 
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controls [61]. Th  is area of enhanced hyper  algesia may 
correspond to the enlargement of spinal cord neuron 
receptive ﬁ  elds, characteristic of central sensitization.
In addition to central augmentation of pain through 
central sensitization and/or loss of descending analgesia, 
functional neuroimaging studies suggest that structures 
in the medial pain system may modulate pain processing 
in RA. Using positron emission tomography, Jones and 
Derbyshire observed that regional cerebral blood ﬂ  ow in 
the dorsolateral prefrontal cortex, anterior cingulate 
cortex and cingulofrontal transition cortex was lower in 
RA patients compared with healthy controls exposed to 
heat pain [62]. More recently, Schwienhardt and colleagues 
showed that fMRI signal intensity in the medial pre-
frontal cortex was signiﬁ  cantly associated with depres-
sion severity among 20 RA patients with provoked joint 
pain [63]. Th  ese  diﬀ  erences in cortical activity may reﬂ  ect 
enhanced cortical opioid peptide release in patients with 
RA [64].
Th   e relationships between inﬂ  ammation, psychosocial 
factors and peripheral and central pain processing are 
intricately entwined. In a recent study of 59 female RA 
patients, we showed that C-reactive protein levels were 
inversely associated with pain thresholds at joint sites but 
not nonjoint sites, consistent with peripheral sensiti  za-
tion [65]. Sleep disturbance, on the other hand, was 
associated with pain thresholds at both joint and nonjoint 
sites, indicating a central mechanism linking pain sensi-
tivity and sleep problems. Recent studies in healthy 
women [66] and in patients with temperomandibular 
joint disorder [67] support this hypothesis, showing that 
short sleep duration and forced awakenings are 
associated with loss of descending analgesic activity.
Mechanism-based treatment
Th   e rheumatologist’s approach to pain management has 
historically focused on treatment of the underlying 
disease process. With recent advances in the study of 
pain mechanisms, it has become clear that pain is 
multifactorial in origin, and successful treatment may 
require a combination of medications with diﬀ  erent 
mechanisms of action. Although most rheumatologists 
are familiar with the use of nonsteroidal anti-inﬂ  am-
matory drugs for pain, few are experienced with newer 
classes of medications, such as antidepressants and anti-
convulsants, that target central pain-processing mecha-
nisms. Current treatments for central pain have mainly 
been used in the ﬁ  bromyalgia population, although a few 
studies have examined these agents in OA patients and 
RA patients. In the remainder of the present review we 
give an overview of the medications that are likely to play 
an increasing role in pain management among patients 
with rheumatic disease.
Tricyclic antidepressants
Tricyclic antidepressants (TCAs) work by inhibiting sero-
tonin and norepinephrine reuptake. Th   e most commonly 
used TCA is amitriptyline. Other TCAs include dothiepin 
and imipramine.
Ten randomized, double-blinded, placebo-controlled 
trials have examined the eﬃ   cacy of amitriptyline in ﬁ  bro-
myalgia [68]. A meta-analysis of these studies revealed 
poor to moderate evidence for the eﬃ   cacy of amitrip-
tyline 25 mg daily over 6 to 8 weeks but no evidence for 
the eﬃ   cacy of amitriptyline at higher doses or longer 
treatment durations. Outcome measures included patient 
and physician global assessment of disease, the visual 
analog pain scale and the tender point count [68]. 
Although these studies were classiﬁ   ed as of high 
methodo  logical quality by Jadad’s score, other quality 
issues (for example, sample size, duration of follow-up 
and retention rates) were not considered and may limit 
the strength of these results.
Studies of TCAs in OA and RA have been limited. To 
our knowledge, no studies have speciﬁ  cally assessed the 
role of TCAs in the treatment of pain in OA – although 
one study examined the eﬃ   cacy of imipramine in the 
treatment of pain in a mixed population of 66 OA, RA 
and ankylosing spondylitis patients, showing signiﬁ  cant 
pain relief in patients treated with imipramine compared 
with placebo [69]. In RA, four out of six studies reported 
signiﬁ   cant improvements in pain among RA patients 
taking TCAs compared with RA patients on placebo 
[70-73]. Th  e largest study, including 184 RA patients, 
showed a decrease in pain among patients treated with 
dothiepin, but the change in pain scores was not 
statistically diﬀ   erent from the change in pain scores 
among patients treated with placebo [74]. Studies 
examining the eﬀ  ects of TCAs on depression and pain 
showed that improve  ments in pain were independent of 
improvements in depression [70,73].
In clinical practice, the use of TCAs is often problem-
atic because TCAs are associated with substantial 
adverse eﬀ  ects, and compliance with these medications is 
low. In addition to inhibiting serotonin and nor  epi  neph-
rine reuptake, TCAs also block cholinergic, histaminic 
and α-adrenergic receptors. As a result, many patients 
taking TCAs experience side eﬀ  ects such as sedation, 
dizziness, blurred vision, constipation and dry mouth. 
Dry mouth is particularly problematic in the RA popu-
lation because many patients also have secondary Sjogren’s 
syndrome, an inﬂ   ammatory disorder characterized by 
decreased salivary gland function.
Serotonin norepinephrine reuptake inhibitors
Serotonin norepinephrine reuptake inhibitors (SNRIs) 
have similar noradrenergic/serotonergic reuptake ratios 
compared with TCAs. While TCAs have many eﬀ  ects 
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reuptake, however, SNRIs are selective. A selective SNRI, 
such as duloxetine or milnacipran, could thus show 
greater overall beneﬁ  t by enhancing the serotonergic and 
noradrenergic eﬀ   ects that lead to drug eﬃ   cacy,  while 
minimizing the dose-limiting eﬀ  ects of toxicity.
SNRIs modulate the descending serotonin–norepi-
neph  rine pathways involved in central pain-inhibiting 
mechanisms and are eﬀ  ective in the treatment of condi-
tions characterized by defects in central pain processing 
(for example, ﬁ   bromyalgia). In a group of 40 healthy 
individuals with low descending analgesic activity at 
baseline, treatment with duloxetine 60 mg daily resulted 
in an increase in descending analgesic activity from 0.15 
to 19.35 within 1 week [75].
Two SNRIs, duloxetine and milnacipran, are approved 
by the Food and Drug Administration for the treatment 
of ﬁ   bromyalgia. In three large, randomized placebo-
controlled trials of ﬁ  bromyalgia patients, duloxetine was 
associated with signiﬁ  cant improvements in clinical pain 
[76-78]. Similar results have been reported in studies 
examining the eﬀ   ects of milnacipran on ﬁ  bromyalgia 
pain [79-81]. Th  e pain-relieving eﬀ  ects of these agents 
have been observed in depressed patients and in non-
depressed patients [79].
Recent studies have expanded the potential use of 
SNRIs to other chronic painful conditions, including OA. 
In a 13-week, randomized, double-blind, placebo-
controlled trial of 231 patients with knee OA, duloxetine 
60 to 120 mg daily signiﬁ  cantly reduced mean 24-hour 
pain scores [82]. Duloxetine was also associated with 
signiﬁ     cant improvements in the Western Ontario and 
McMasters physical function scores. To date, no studies 
have examined the eﬀ  ect of SNRIs on pain in RA.
The α2δ ligands
Th  e α2δ ligands, pregabalin and gabapentin, are anti-
convulsants used to treat chronic pain conditions such as 
postherpetic neuralgia and diabetic neuropathy. 
Pregabalin and gabapentin bind to the α2δ subunit of 
calcium channels, inhibiting the release of neuro  trans-
mitters, including glutamate, noradrenaline, serotonin, 
and substance P. Th  ese compounds could thus work in 
individuals with central sensitization, as well as decreased 
descending analgesic response due to low serotonergic–
noradrenergic activity.
Among ﬁ   bromyalgia patients, pregabalin has con  sis-
tently been associated with improvements in pain 
severity [83,84]. A Cochrane systematic review including 
1,376 ﬁ  bromyalgia patients treated with pregabalin 300 
to 450 mg daily reported a relative beneﬁ  t between 1.5 
(95% conﬁ  dence interval 1.2 to 1.9) and 1.7 (95% conﬁ  -
dence interval 1.4 to 2.1) for a 50% decrease in pain [85]. 
Th   e authors concluded that although some patients will 
experience moderate pain relief from pregabalin, few will 
experience a large eﬀ  ect [85]. No studies have examined 
the eﬀ  ect of pregabalin on pain in OA or RA patients, 
although a recent animal study suggested that pregabalin 
decreased pain sensitivity in a rat model of OA [86].
Conclusions
Central pain mechanisms play important roles in wide-
spread pain syndromes, including ﬁ  bromyalgia. Th  e  role 
of these mechanisms in rheumatologic diseases such as 
OA and RA is not well understood. A few small studies, 
utilizing quantitative sensory testing and fMRI, have 
documented loss of descending analgesic activity and 
alterations in CNS activity among OA patients, and a 
couple of small studies suggest a role for central sensiti-
za tion  in RA (Table 1). Th   e data regarding loss of descend-
ing analgesic activity in RA, however, remain inconclusive.
Larger studies involving extensive pain phenotyping 
and comprehensive information about disease charac  ter-
istics are necessary to better understand the impact of 
central pain mechanisms in OA and RA. Studies are also 
neces  sary to determine whether these patients, or a sub-
group of these patients, may beneﬁ  t from treatment with 
drugs such as SNRIs and α2δ ligands that target central 
pain mechanisms. If central pain mechanisms do play a 
signiﬁ  cant role in pain processing among OA and RA 
patients, these medi  ca  tions may be attractive adjunctive 
treatments to manage pain in patients with rheuma  to-
logic disease.
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